RxDoctor Payments Data

Koppany Visnyei, MD

Internal Medicine · Los Angeles, CANPI 1770897365

Payments from drug & device makers

$304,949in general payments, 2019–2025

Across 1,368 payments — averaging $222.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$259K
  • Gilead$32K
  • EMD Serono, Inc.$2K
  • Johnson & Johnson$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Amgen$1K
  • plus $8K from 43 others

What the payments were for

  • Consulting fees$65,85323%
  • Speaking & faculty fees$149,04052%
  • Travel & lodging$40,57714%
  • Food & beverage$31,23311%
  • Education$4460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304,949 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$369,452
Medicare patients
191
Services billed
16,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala124$527,133
SerostimSomatropin13$434,838
DovatoDolutegravir Sodium/Lamivudine86$262,419
TivicayDolutegravir Sodium91$233,362
PrezcobixDarunavir/Cobicistat52$166,164
JulucaDolutegravir/Rilpivirine41$153,413
RukobiaFostemsavir Tromethamine13$115,252
DescovyEmtricitabine/Tenofov Alafenam35$78,499
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$72,422
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$57,039
TriumeqAbacavir/Dolutegravir/Lamivudi14$48,361
Repatha SureclickEvolocumab45$35,585
OzempicSemaglutide14$30,921
Testosterone91$25,580
FarxigaDapagliflozin Propanediol28$20,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Rukobia, Triumeq$259,415$812,806245 claims
GileadBiktarvy, Descovy$32,131$605,633159 claims
EMD Serono, Inc.Serostim$1,594$434,83813 claims
Johnson & JohnsonPrezcobix$1,329$166,16452 claims
Janssen Products, LPSymtuza$446$72,42214 claims
Novo NordiskOzempic$169$30,92114 claims
AstraZenecaFarxiga$327$20,35928 claims
MerckJanuvia$1,139$18,02319 claims
Lilly USA, LLCMounjaro$274$12,53311 claims
GSKAnoro Ellipta$226$5,60312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →